Product details
Background：IL-31 is a cytokine belonging to the IL-6 family-related chemokine lineage, encoding a precursor protein that is secreted into an active form after splicing. It is regulated by inflammatory signals and barrier damage, etc. , the promoter region is regulated by STAT, NF-κb and other pathways, and there may be tissue-specific splice variants. IL-31 is mainly expressed in skin-associated immune cells (such as Th2 cells, mast cells, dendritic cell, etc.) and epithelial cells, with systemic baseline expression but higher in local inflammatory sites; It is closely related to inflammatory environment, barrier damage, infection and allergic reaction. Its function is to form a heterodimer with the receptor IL-31RA and co-receptor OSMR β, which activates Jak/STAT, MAPK and other signaling pathways, it promotes pro-inflammatory response, cell proliferation and differentiation, as well as neuro-immune coupling and itch signaling, and participates in pathological processes such as eczema/atopic dermatitis and chronic pruritus. In terms of drug development, targets can be IL-31 ontology, IL-31RA or OSMR β, and antibody drugs need to take into account cross-species differences, structure-function relationships, and coordinated regulation of local and systemic inflammation in the skin, and combined with biomarkers to achieve patient stratification treatment.
